RJA
DNLI icon

Raymond James & Associates’s Denali Therapeutics DNLI Stock Holding History

Raymond James & Associates’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,894
Closed -$204K – 3854
2023
Q3 		$204K Sell
9,894
-137
-1% -$3.48K ﹤0.01% 3443
2023
Q2 		$296K Sell
10,031
-1,376
-12% -$38.7K ﹤0.01% 3267
2023
Q1 		$263K Buy
11,407
+1,490
+15% +$41K ﹤0.01% 3325
2022
Q4 		$276K Buy
+9,917
New +$295K ﹤0.01% 3271
2022
Q1 		– Sell
-4,926
Closed -$220K – 4152
2021
Q4 		$220K Sell
4,926
-1,245
-20% -$59K ﹤0.01% 3642
2021
Q3 		$311K Sell
6,171
-218
-3% -$12.3K ﹤0.01% 3382
2021
Q2 		$501K Sell
6,389
-1,096
-15% -$67.8K ﹤0.01% 3083
2021
Q1 		$427K Sell
7,485
-47
-0.6% -$3.15K ﹤0.01% 3131
2020
Q4 		$631K Buy
+7,532
New +$455K ﹤0.01% 2654

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's DNLI Position: Q4 2023 in Review

Raymond James & Associates sold out of Denali Therapeutics (DNLI) in Q4 2023, closing a stake of 9,894 shares — an estimated $204K sold.

Raymond James & Associates first reported a position in DNLI in Q4 2020 and held it in 9 quarters. The position peaked at $631K in Q4 2020. 209 funds tracked by Wall St. Rank hold DNLI as of Q4 2023.

  • Raymond James & Associates reported no remaining Denali Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 9,894 Denali Therapeutics shares in Q4 2023, an estimated $204K.
  • Raymond James & Associates first reported a position in Denali Therapeutics in Q4 2020 and held it in 9 quarters.
  • Raymond James & Associates's Denali Therapeutics position peaked at $631K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.